Abstract
INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas, accounting for about 90% of malignant pancreatic neoplasms. The most important imaging diagnosis to differentiate from PDAC are neuroendocrine tumours [1, 2] . Most pancreatic cystic neoplasms are mucin producing including intraductal pancreatic mucinous neoplasia (IPMN) and mucinous cystic neoplasia (MCN) [3] . Other important pancreatic lesions to differentiate include metastases (e.g., of renal cell cancer), lymphoma and ectopic spleen. Comparatively less is known about serous pancreatic neoplasia (SPN) which is a rare (less than 1%-2% of pancreatic neoplasia) and predominantly cystic appearing tumor of the pancreas. Critically SPN is considered benign in comparison to the majority of other common cystic tumors and all solid tumors of the pancreas. SPN has been previously termed serous pancreatic cystic neoplasia and serous pancreatic cystadenoma [4] . Approximately 75% of SPNs are found in women at an average age of 50-60 years, however SPN may also be found in much younger patients [5] . Typically located in the body-tail of the pancreas and solitary, the majority are detected incidentally [4, [6] [7] [8] . In the largest series published to date (n = 2622), 61% of patients were asymptomatic and 27% reported non-specific abdominal complaints, whilst only 9% presented with pancreatobiliary symptoms, and 9% with other symptoms [5] . Histopathologically, SPNs are cyst-forming epithelial neoplasms composed of cuboidal, glycogen-rich, epithelial cells, without cellular atypia. The cyst content is defined as "clear watery". SPNs lack the genetic alterations typical of PDAC, pancreatic neuroendocrine tumors, and mucinous cystic neoplasms of the pancreas (MCN and IPMN). Rather, they are characterized by molecular alterations of the von-Hippel-Lindau (VHL) gene and overexpression of vascular endothelial factor (VEGF), glucose transporter 1, and other markers of clear-cell tumorogenesis (HIF1-α, CAIX) [9] . VHL patients have a high prevalence of pancreatic lesions (unclassified benign cysts, neuroendocrine tumors, SPNs) and often multiple tumors in the gland. A systematic review found SPN in 11% of VHL patients [10] . However, the majority of SPNs are sporadic.
Most serous neoplasms are benign and defined as serous cystadenomas (SCAs). More aggressive subtypes occur, demonstrated in a series of 257 resected SCAs; 5.1% of SPNs were locally aggressive, with invasion of surrounding structures or vasculature or direct extension into peripancreatic lymph nodes, while 0.8% were frankly malignant, given the presence of metastases [5] . Another series of 193 SPNs reported infiltration of adjacent organs and structures in 3% of cases, but called into question the term "malignancy" for cases of very large SPNs [11] . Rare cases of synchronous or metachronous hepatic SPNs may represent multifocal occurrence rather than metastatic spread [9] . Frankly malignant behavior with metastases seems to be very rare. In a multinational study of 2622 patients with SPNs, only 3 serous cystadenocarcinomas (SCACs) were recorded (0.1%) [8] . Therefore, SCAC is represented predominantly by a few sporadic case reports in the recent literature. Follow-up studies have not demonstrated proof of an adenoma-carcinoma sequence in SPN [8, 9, [11] [12] [13] [14] [15] . The growth rate of SPNs is variably reported. In the largest series (n = 2622) it was found to be only 4 mm/ year, and size was stable or decreased in as many as 63% of patients [8] . This was supported by another series (n = 214), where the doubling time was estimated at approximately 12 years, and was independent of tumour size [14] . In contrast, in another case series (n = 106) growth rate was reported to vary by tumor size, with the fastest growth (20 mm/year) observed in tumors ≥ 40 mm, compared to tumors < 40 mm (increasing 12 mm/year) [16] . Finally, a fourth series (n = 145) found the fastest growth 7-10 years after diagnosis (60 mm/year) compared to the first 7 years (10 mm/year). Oligocystic or macrocystic appearance, a history of other tumors, and patient age were all significant predictors of more rapid tumor growth [13] . Diagnosis of SPN primarily is based on imaging [computed tomography (CT); magnetic resonance imaging (MRI); ultrasound (US); endoscopic ultrasound (EUS)]. The classical microcystic SPN consists of innumerable very small cysts separated by thin, vessel-containing fibrous septae. Cysts may be microscopic or measure up to 10 mm. These features cause a honeycomb or sponge-like appearance with hypervascularity and distinct, sometimes lobulated, margins. Pertinent negatives include communication with the pancreatic duct, vascularized mural nodules, and a hypervascular capsule on contrast-enhanced imaging, whilst a central scar is visible in a third of cases and may contain calcifications [17] [18] [19] [20] [21] [22] [23] [24] [25] . Pitfalls may arise from several factors: the macro-and oligo-cystic types of SPN can appear similar to pseudocysts or MCN. Rarely the solid form of SPN may be confused with other hypervascular well-circumscribed pancreatic tumors, in particular neuroendocrine tumors and solid pseudopapillary neoplasms [18, 19, [26] [27] [28] . In contrast to the mentioned reports, an atypical appearance on CT was found in 61.1% of cases in a study of 72 confirmed SPNs [28] . A correct diagnosis of SPN is challenging. The preoperative diagnosis was wrong in 63% of resected cases in a Japanese series [12] , and in a large multinational study the indication for surgery was an uncertainty of diagnosis in 60% of cases [8] . To date, no large series describing typical and atypical US-and EUS-features of SPNs has been reported.
The aim of this retrospective study was to describe the imaging features of serous neoplasms of the pancreas using US, EUS, CT and MRI. The frequency of atypical imaging aspects by different imaging modalities will be estimated and the most common atypical features will be reported, particularly of US which is often the initial imaging modality employed.
MATERIALS AND METHODS

Patients
An international multicenter retrospective data collection of 287 histologically confirmed cases of SPNs was performed. The cohort was not uniform according to the resection criteria. No other exclusion criteria have been defined.
Examination technique
Conventional ultrasound and contrast enhanced ultrasound (CEUS) were performed in all patients with one of six ultrasound systems: Philips iU22 unit (Philips Bothell, WA, United States; C5-1 convex array probes, 1-5 MHz), or LOGIQ E9 (GE Healthcare, Milwaukee, WI, United States; C1-5 convex array probes, 1-5 MHz) or Hitachi (Hi vision EUB-6500, Preirus, Ascendus; C715 convex array probes, 1-5 MHz), or SIEMENS (Acuson Sequoia or S2000), or Toshiba (Aplio platinum 500; Aplio CV, convex array probes 3-6 MHz). CEUS was performed using contrast harmonic real-time imaging at a low MI 0.05-0.30. The ultrasound contrast agent Sonovue was used at a dose of 1.5-2.4 mL, immediately followed by an injection of 10 mL sodium chloride solution. Images were recorded for 3 min after contrast agent injection.
Contrast enhanced EUS was performed using longitudinal echoendoscopes EG-3870 UTK and Hitachi platforms (Hitachi HI vision EUB-6500, Hitachi Preirus, Hitachi Ascendus) [29] [30] [31] [32] .
Imaging Evaluation (TUS, EUS, CEUS, ceEUS)
After identification of the pancreatic lesion by conventional B-mode US or EUS, contrast enhanced imaging was immediately performed. All examinations were interpreted according to the 2011 EFSUMB guidelines [1] . CEUS features of pancreatic lesions were compared to the surrounding normal pancreatic parenchyma.
Final diagnoses, treatment and clinical follow up
Most patients (n = 249, 86.7%) were diagnosed as SPNs by post-operative histopathology. 31 (10.8%) cases were confirmed by EUS FNA and 7 (2.5%) by transabdominal (percutanous) ultrasound-guided core needle biopsy (18-gauge 20-cm single-use biopsy needles; Temno, Germany, or BioPince, Pflugbeil, Germany). Clinical follow-up for a minimum of 12 mo was established for all patients with SPN diagnosed by biopsy. Additional information on outcome data was not requested.
Statistical analysis
Statistical analyses were performed using SPSS Statistics 17.0 (SPSS Inc., Chicago, IL, United States).
The χ 2 test and Fisher's exact test were used to compare categorical parameters between the groups. Continuous parameters were presented as the mean ± SD, and Student's t test was used. A P value of less than 0.05 was considered statistically significant.
RESULTS
Epidemiology
The average age of included patients was 57.3 ± 14.2 years (18-85 years). Fifty-eight patients were male and 229 were female (Table 1) .
Conventional ultrasound
On conventional B mode ultrasound (BMUS) most SPN lesions (n = 113, 39.3%) were detected in the head/ neck of the pancreas. Most SPN lesions (97.9%) were (61.8%) in the arterial phase. During the late phase, most SPN lesions were hyper-enchancing (22.5%) or iso-enhancing (74.9%) ( Table 3 ).
EUS and contrast enhanced EUS
EUS was performed in 61 patients diagnosed with SPN. Using CDI, macrovessels were detected in all 61 cases. Contrast enhanced endoscopic ultrasound (CE-EUS) was performed in 54 SPN lesions, demonstrating hyper-enhancement in all cases (Table 4) .
DISCUSSION
SPNs are less frequent than common pancreatic tumors such as solid ductal adenocarcinoma and cystic IPMN but recent estimates suggest SCAs represent about 20% of all cystic pancreatic lesions [33, 34] . SPN typically present as a solitary multilocular microcystic lesion with a honeycomb architecture due to the presence of multiple microcysts. Thin walls and multiple thin septa orient toward the centre/ scar of the lesion, without communication with the main pancreatic duct. In typical cases an imaging diagnosis can be made confidently. However, atypical presentations are commonly encountered in everyday clinical practice. Specifically, extremely microcystic SPNs are considered rare, resembling a solid lesion in conventional US, but in fact a solid component was seen in the 55.7% of cases in our multicentre study. After contrast administration, these solid SPNs may resemble hypervascular solid lesions with homogeneous hyperenhancement, making differentiation from neuroendocrine neoplasms as difficult as it is crucial [35, 36] . MRI may reveal a lesion's true cystic nature [37] . The macrocystic variant must be differentiated from other macrocystic pancreatic lesions, such as pseudocyst, mucinous cystic neoplasms, sidebranch and mixed type IPMNs, solid tumors (either adenocarcinomas or neuroendocrine) with cystic degeneration, and lymphangiomas [38] [39] [40] .
Epidemiology
The mostly asymptomatic SPN is often a solitary lesion with multilocular cysts predominantly in the corpus and tail of the pancreas. SPNs are usually diagnosed single, though 6 (2.1%) patients had multiple lesions, and most lesions (97.9%) were hypoechoic on BMUS. With colour Doppler imaging (CDI), macrovessels were detected in 20.6% of lesions, among which the typical "spoke wheel" appearance was identified in 35.6% of lesions ( Table 2) .
CEUS
Transabdominal CEUS was performed in 173 (60.3%) lesions. After contrast agent injection, most SPN lesions displayed hyper-(36.5%) or isoenhancement in females in the 5 th to 7 th decade (female to male ratio 2-3:1) but with improved imaging methods the neoplasia may be diagnosed much earlier [3] . Multiple lesions, including involvement of the entire organ, have been observed in patients with Von Hippel-Lindau disease [6, 7, 10, 23] . SPNs may present up to 20% of cystic pancreatic lesions [3, 33, 41] .
Clinical symptoms
Sporadic and benign SPNs are most often an incidental finding without symptoms; jaundice is particularly uncommon. In our series only 5.2% of SPNs presented with symptoms. During the course of the disease, symptoms may be caused by growth of the lesion. The main pancreatic duct and or common bile duct may become entrapped in the lesion, especially if large in dimension. The reported growth rate has been estimated at 4 mm per year [39] .
Pathology
The solitary well demarcated and multicystic SPN is a multilobular cyst forming epithelial neoplasia with a somewhat "honeycomb" architecture ( Figure 1 ) without communication with the pancreatic duct.
Histologically, monostratified cuboidal, glycogen rich epithelial cells typically without mitoses are observed. Centrally located fibrous tissue (a so called "scar") with or without calcifications can be found, similar to focal nodular hyperplasia of the liver; therefore the lesion has been referred to as "FNH of the pancreas" [4] . SPNs are typically hypervascular lesions, where septa are characterized by abundant subepithelial micro-and macro-vessels [6, 7] .
Size of single cysts
According to the size of the cysts, SPNs can be classified as real solid lesions (< 5%), pseudo-solid SPNs (cysts only detectable by microscopic evaluation), microcystic (< 10 mm), oligocystic (< 20 mm), and macrocystic appearance (30%) [4, 6, 7, 42, 43] . The cystic appearance can be described by thin multiple septa oriented toward the center of the lesion. Mixed forms (microcystic and macrocystic) are typical in large SPNs. Macrocystic giant SPNs are more commonly located in the pancreatic head, and a male preponderance was observed. The macrocystic variant may be indistinguishable from other macrocystic tumors of the pancreas [44] .
Malignant transformation
SPN is typically a benign neoplasia but in a series of 257 resected SPNs, local expansion (5.1%) and malignant transformation with metastases (0.8%) have been described [5] . Therefore, follow-up is recommended by means of ultrasound or MRI. Surgical treatment is recommended only for symptomatic patients or patients with growing lesions, usually larger than 4 cm [16] .
Imaging
Ultrasound: Sonographically, SPN is a typically lobular cyst forming isoechoic neoplasia with centrally oriented thin walls (thin septae) without communication with the main pancreatic duct. A central hypoechoic spot (central fibrovascular scar) is characteristic [3, [45] [46] [47] . In the case of depictable cysts the content is anechoic. SPNs are typically hypervascular lesions since the septa are composed by abundant subepithelial microand macro-vessels [6, 7] (Figures 2 and 3) .
As has been shown in a prospective study (n = 12) using CE-EUS, hypervascularity, sharp delineation, fibrotic strands and typical vessel architecture are the predominant features of serous microcystic adenoma [47] (Figures 4 and 5 ).
Solid SPNs may mimic neuroendocrine tumours, renal metastases, intrapancreatic accessory spleens and other hypervascular pancreatic tumours [35, 36, 45, 48] . Solid and pseudosolid SPNs are typically hypervascular and, therefore, hyperenhancing using CEUS [45, 48, 49, 50] . EUS: EUS is an accurate imaging modality to diagnose and exclude neoplasia of the pancreas [1, [51] [52] [53] . The features are the same as described for conventional ultrasound [54] . SPN do not communicate with the main pancreatic duct but may show proximal duct dilatation due to compression, whereas IPMN usually showed distal or whole pancreatic duct dilatation [50, 55] . CE-EUS has been proven to be of value for many indications [29] [30] [31] [32] [56] [57] [58] [59] [60] . In our study EUS was able to detect macrovessels and hypervascularity by CDI contrast-enhanced imaging in 100% of cases, whereas percutaneous US with CDI delineated macrovessels only in 20.6% of cases.
Endoscopic ultrasound fine needle aspiration:
Endoscopic ultrasound fine needle aspiration (EUS-FNA) of SPN should target the largest cyst for fluid analysis [61, 62] . The cyst fluid is watery (non-viscous) and colorless [63] . The cellularity is low with few cuboidal glycogen positive and mucin negative epithelial cells. CEA levels are usually but not always low (< 20 ng/mL). In the majority of cases, aspirated fluid will be hypocellular with few groups of bland cuboidal epithelial cells embedded in granular debris [64] [65] [66] [67] . Round to cuboid serous epithelial cells with clear cytoplasma and small, round nuclei forming loose clusters or monolayered sheets are identified in only 20%-25% of cases [64, 66, 68] . Positive α-inhibin immunocytochemistry may enhance the diagnostic accuracy of EUS-FNA in SPN [66] . Promising cyst fluid markers with high sensitivity and specificity for SPN include VEGF-A and a molecular assay for KRAS, GNAS and VHL mutations. In one study, VEGF-A was markedly elevated in SPN when compared to pseudocysts and mucinous neoplastic cysts [69, 70] . The presence of KRAS and GNAS mutations is highly specific for IPMN and is never observed in SPN, whereas VHL deletions are found in almost all SPN [69, [71] [72] [73] [74] .
Core biopsy: In solid and pseudosolid lesion we prefer histological evaluation which allows definite diagnosis [51, 52, 75] .
MRI:
The MRI features of SPNs are also represented by a typical lobular "honeycomb" shaped contour and architecture with thin walls less than 2 mm, in contrast to other cystic neoplasia of the pancreas. SPNs are homogeneously hypointense on T1-weighted MRI sequences. The cystic nature of the lesion can be easly demonstrated by a typical hyperintense signal on T2-weighted images. The hyperintense cysts are surrounded by hypointense septa and sometimes by a hypointense (pathognomonic) central scar. The central scar is a less sensitive (15%) but specific sign of SPN [39, 45, [76] [77] [78] [79] . In contrast to EUS, the individual vessels cannot be displayed but contrast enhanced MRI using gadolinium chelates also reveal the hypervascular nature by diffuse hyperenhancement in pseudosolid SPN However also in pseudosolid SPN, MRI remains highly accurate in showing the cystic nature of the lesion on T2-weighted images [50] . The macrocystic types present features similar to other macrocystic tumors of the pancreas, but the lobulated contours, together with the absence of wall enhancement and wall thickness less than 2 mm, should suggest the correct diagnosis [39, 46, 76, 79] . CT: CT is sometimes helpful for detection of SPN but should in general not be used for the evaluation and differential diagnosis of cystic pancreatic lesions. CT might be helpful in the visualization of a centrally located calcified scar. SPN may mimic a hypervascular lesion [17, 39, 46] .
Differential diagnosis
The presence of a unilocular lobulated cyst located in the pancreatic head with anechoic fluid and wall thickness less than 2 mm are indicative of SPN using all imaging methods and should be considered as a unilocular macrocystic SCA, until otherwise proven (Figures 6-8 ) [80] .
Pancreatitis:
A clinical history of pancreatitis is crucial for differentiating pseudocysts. Imaging findings of pancreatitis derived pseudocysts include signs of inflammation in the acute setting, calcifications, thinwalled duct dilation, pancreaticolithiasis, and atrophy and typical dilation of the pancreatic duct [39, 51, 81, 82] .
Solid SPNs are often misdiagnosed as chronic (focal) pancreatitis, which is important to know. 
MCN:
MCNs are also most common in females and they do not communicate with the pancreatic duct, but are usually located in the pancreatic tail [83] . The complex internal architecture of MCNs including septa and mural nodules can be best visualized using EUS and contrast enhanced EUS, but cMRI may be also helpful. In EUS-FNA, mucin and evaluation of the CEA level is important [39] . Peripherally located eggshell calcifications are a specific sign of MCN [84] . Other rare differential diagnoses include solid papillary neoplasia and lymphoepithelial cysts [39] .
In conclusion, serous pancreatic neoplasms are an important differential of cystic, mixed and solid pancreatic lesions, with a generally benign course. This large series of histologically proven cases demonstrates the typical demographic, structural, vascular and contrast enhancement features which can distinguish these lesions from more common pathologies.
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